StockIQpro
NASDAQ:RAPP

Rapport Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Rapport Therapeutics, Inc. reported net income of −$111.5M in fiscal 2025. Free cash flow was −$88.1M, and the diluted share count rose 87.7%.Summary generated from Rapport Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 10, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−28.2%
Debt / equityn/a
Free cash flow−$88.1M
FCF marginn/a
Share count change+87.7%

Financials

Fiscal years, $M
Item202320242025
Revenuen/an/an/a
Operating income−36−83−125
Net income−35−78−111
Free cash flow−29−67−88

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations